Bellerophon Therapeutics inc  (BLPH)
Other Ticker:  
Price: $0.0533 $0.00 2.303%
Day's High: $0.0533 Week Perf: 4.51 %
Day's Low: $ 0.05 30 Day Perf: -11.9 %
Volume (M): 166 52 Wk High: $ 12.58
Volume (M$): $ 9 52 Wk Avg: $2.47
Open: $0.05 52 Wk Low: $0.03

 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 12
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -9
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Bellerophon Therapeutics Inc
Bellerophon Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative treatments for cardiopulmonary diseases. The company's main product candidate is INOpulse', a proprietary pulsatile nitric oxide delivery system designed to improve a patient's quality of life. INOpulse' is currently being evaluated in multiple clinical trials for various indications, including pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Bellerophon Therapeutics aims to address unmet medical needs in the field of cardiopulmonary diseases and improve patient outcomes through its therapeutic solutions.

   Company Address: 20 Independence Boulevard Warren, 7059 NJ
   Company Phone Number: 574-4770   Stock Exchange / Ticker: NASDAQ BLPH
   BLPH is expected to report next financial results on March 30, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc. Drives Efficiency and Reduces Losses, Garnering Attention in the Major Pharmaceutical Preparations Industry

As the major pharmaceutical preparations industry observers analyze the financial results of the third quarter of 2023, one company that stands out is Bellerophon Therapeutics Inc. Despite not providing any specific top-line figures yet, the company has demonstrated significant improvement in its operating shortfall compared to the same period in the previous year. With a more efficient and strategic approach, Bellerophon Therapeutics Inc. has reduced its losses and is expected to release its next financial earnings report on March 30, 2024.
Evolving Efficiency and Financial Growth
In the third quarter of 2023, Bellerophon Therapeutics Inc. showcased its ability to work more competently compared to the same interval in the previous year. The company's operating shortfall reduced from $-5.116 million to $-2.17 million, indicating a significant improvement in financial performance.

Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc Faces Investor Concerns as Operating Losses Mount in Q2 2023

Investors Concerned as Bellerophon Therapeutics Inc Reports Operating Loss and Net Loss
Bellerophon Therapeutics Inc (BLPH), a prominent biopharmaceutical company, has recently shared its financial performance for the earnings cycle of fiscal April to June 30, 2023. While shareholders had not anticipated any significant changes during this period, they have closely monitored the company's operating loss, which amounted to $-5.259 million. This significant loss has overshadowed the results in the same period last year, indicating a concerning trend in productivity.
The primary takeaway from this news is that Bellerophon Therapeutics Inc, primarily focused on its development phase, has experienced challenging times in their financial performance. Additionally, the last quarter of 2023 revealed a net loss of $-5.138 million, signifying a substantial increase from the $-4.105 million loss in the comparable period a year ago. These numbers raise further concerns surrounding the company's financial stability.

Bellerophon Therapeutics Inc

Bellerophon Therapeutics Inc. Sees Impressive Earnings Growth Fueled by $1.28 Million Tax Benefit in Q1 2023

Bellerophon Therapeutics Inc. (BLPH) has reported an impressive revenue of $5.706 million in the financial span ending March 31, 2023. The Major Pharmaceutical Preparations company saw a significant improvement in its bottom-line, with a net profit of $2.822 million compared to a net loss of $-5.641 million in the corresponding quarter last year. However, it is important to note that the earnings growth was supported by the $1.28 million tax benefit. Without this tax benefit, the earnings for Q1 2023 would have been more modest.
In addition to the impressive revenue growth, Bellerophon Therapeutics highlighted its improving profit margins as well. The company's net margin rose to 49.46% in the financial span ending March 31, 2023, while its operating margin edged up to 25.92%. These numbers indicate that BLPH's strategy of focusing on profitability is starting to pay off.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com